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Abstract
One of the objectives of the Paediatric Regulation (EC) No 1901/2006, is to foster high quality ethical research on
medicinal products to be used in children. To achieve this objective, the EMA is responsible for developing a
European paediatric network of existing national and European networks and centres with specific expertise in
research and clinical trials relating to paediatric medicines. The purpose of this article is to disseminate knowledge
of the structure and goals of ENPR-EMA and to highlight the cultural and organizational difficulties for its
implementation.
Following the publication of research quality requirements, a set of recognition criteria, which have to be fulfilled
to become a member of ENPR-EMA were agreed. So far, 32 networks and centres (of 62 identified networks)
submitted self-assessment reports indicating whether or not they fulfill the agreed minimum criteria. Sixteen
networks (26% of 62 identified networks) fulfilled all minimum criteria and became therefore members of ENPR-
EMA. The Family Paediatricians Medicines for Children Research Network (FIMP-MCRN), established with the aim of
developing competence, infrastructure, networking and education for paediatric clinical trials, became member of
the ENPR-EMA responding satisfactorily to all the points of the self-assessment report.
Introduction
One of the objectives of the Paediatric Regulation (EC)
No 1901/2006, is to foster high quality ethical research
on medicinal products to be used in children [1,2].
This Regulation aims to facilitate the development and
accessibility of medicinal products for use in the paedia-
tric population, to ensure that medicinal products used
to treat the paediatric population are subject to ethical
research of high quality and are appropriately authorized
for use in the paediatric population, and to improve the
information available on the use of medicinal products
in the various paediatric populations. These objectives
should be achieved without subjecting the paediatric
population to unnecessary clinical trials and without
delaying the authorisation of medicinal products for
other age populations [1].
A scientific committee, the Paediatric Committee,
within the European Medicines Agency with expertise
and competence in the development and assessment of
all aspects of medicinal products to treat paediatric
populations [1].
The Paediatric Committee is primarily responsible for
the scientific assessment and agreement of paediatric
investigation plans and for the system of waivers and
deferrals thereof; it should also be central to various
support measures contained in this Regulation. In its
work, the Paediatric Committee consider the potential
significant therapeutic benefits for the paediatric
patients involved in the studies or the paediatric popula-
tion at large including the need to avoid unnecessary
studies. Correspondence: ettorenapoleone@tiscali.it
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any medium, provided the original work is properly cited.Clinical trials in the paediatric population may require
specific expertise, specific methodology and, in some
cases, specific facilities and should be carried out by
appropriately trained investigators. A network, which links
existing national and Community initiatives and study
centres in order to build up the necessary competences at
Community level, and which takes account of Community
and third country data, would help facilitate cooperation
and avoid unnecessary duplication of studies [1].
This network should contribute to the work of
strengthening the foundations of the European Research
Area in the context of Community Framework Pro-
grammes for Research, Technological Development and
Demonstration Activities, benefit the paediatric popula-
tion and provide a source of information and expertise
for industry[1].
The Article 44 of the Paediatric Regulation (EC) No
1901/2006 included [1]:
1. The Agency shall, with the scientific support of the
Paediatric Committee, develop a European network of
existing national and European networks, investigators
and centres with specific expertise in the performance
of studies in the paediatric population.
2. The objectives of the European network shall be to
coordinate studies relating to paediatric medicinal pro-
ducts, to build up the necessary scientific and adminis-
trative competences at European level, and to avoid
unnecessary duplication of studies and testing in the
paediatric population.
ENPR-EMA (European Network of Paediatric
Research at the European Medicines Agency)
The European Paediatric Regulation calls for the foster-
ing of high-quality, ethical research on medicinal pro-
ducts to be used in children. To achieve this objective,
the EMEA is responsible for developing a European pae-
diatric network of existing national and European net-
works and centres with specific expertise in research
and clinical trials relating to paediatric medicines. The
purpose of this article is to disseminate knowledge of
the structure and the goals of ENPR-EMA and to high-
light the cultural and organizational difficulties for its
implementation.
Detailed goals of ENPR-EMA [3]
The short term and long term goals of the network
encompass:
Collaboration
- identify, co-ordinate and link together existing
networks
- ensure efficient, timely communication and exchange
of information between networks inside and outside the
EU, including with WHO
- be a source of information and expertise for health
professionals
- provide a forum for scientific discussion related to
paediatric clinical trials with all stakeholders, where
necessary
Building competences
- define scientific and operational quality standards, and
recognition criteria by networks themselves for the pur-
pose of the operation of the network in particular not
yet covered by existing quality standards (e.g. GCP)
- develop and agree training and education curricula
and provide training to network partners
- stimulate the development of new networks, centres
and investigators
- organise and hold scientific meetings to discuss spe-
cific topics as identified by the Coordinating Group
- stimulate research on trial methodology and educate
Avoiding unnecessary studies
- avoid duplication of clinical trials in children by shar-
ing information with European as well as international
partners, in particular through the use of EudraCT
develop multidisciplinary research partnership
Stimulating high quality research
- raise awareness on the need for clinical trials for children
and increasing understanding of the purpose of research
- contribute to GCP compliance
- advocate for ethical clinical research, especially when
trials include patients outside the EU.
Strengthening the foundation of the European Research
Area
- Support development and research into off-patent
medicines for children, including contribution to priority
list of off-patent medicines
- stimulate research in areas of relevance such as trial
methodology or non-invasive assays
Facilitation of implementation and recruitment of clinical
trials
- enable rapid attainment of sample sizes large enough
to allow valid conclusions through effective network col-
laboration and facilitation of performance of trials across
Member States; this is especially relevant and crucial for
paediatric trials.
Steps for ENPR-EMA organisation
On 16 February 2009 the EMEA convened a one-day
workshop to discuss and initiate the development of this
European paediatric network. Following a call for
expression of interest, 62 networks and/or clinical trial
centres have been identified [4].
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reminded of the European Paediatric Regulation and the
objectives of this EMEA European network, and the role of
the Paediatric Committee (PDCO). The link with the pae-
diatric investigation plans, the extent of clinical trials pro-
posed and the wide range of therapeutic areas addressed so
far by the PDCO were highlighted, as it is expected that
the network will be involved in performing the trials
requested by the Paediatric Investigation Plans (PIP).
In the second sessions the proposed organisation and
structure of the future European paediatric network
were presented as laid out in the Implementation strat-
egy, adopted by the EMEA Management Board follow-
ing a large consultation process.
Two break-out sessions were held to brainstorm and
discuss the possible structure and operational model for
the European network as well as communication strate-
gies (Group 1), and quality standards and recognition
criteria (Group 2).
Group 1 discussed the composition of the future
“Coordinating Group” as proposed by the implementa-
tion strategy. The participants of this break-out session
concluded that the coordinating group should aim at
being as diverse as possible, representing various types
of networks: on specific therapeutic areas, on specific
needs/age subsets or specific activities and organiza-
tional, transversal networks to cover all areas of paedia-
tric research. It was discussed that clinical trial centres
are usually more interested in phase I-III studies
whereas a network able to mobilise community paedia-
tricians would be more appropriate for the conduct of
long-term follow-up, phase IV studies.
With regards to communication, the need and impor-
tance for external communication with all stakeholders
(industry and patients’ organisations) was stressed.
Relating to internal communication some participants
reported from their experience that in addition to time-
saving communication ways, such as e-mails, telephone
and/or videoconferences, at least one or two meetings
per year, inviting all members, proved to be helpful and
were highly appreciated to overcome potential misun-
derstandings due to language barriers and different cul-
tures across Europe.
G r o u p2w a st a s k e dt od e f i n e“recognition criteria”.
Proposals for recognition criteria included:
￿ Capacity to involve patients from both the design
point of view and the recruitment
￿ Expertise in the therapeutic area
￿ Capacity to manage trials and to perform according
to GCP
￿ Capacity to build up competence and involve further
centres
￿ Capacity to innovate in trials (e.g. methodology, use
of microassays)
￿ Established quality assurance of the network
￿ Potential conflicts of interest
It was considered necessary to first precise the goals of
the European network and the topics on which net-
works want to work together [4].
On 16 March 2010 the EMA convened a one-day fol-
low-up workshop on the European paediatric research
network. Following the outcome of the first workshop
with participants of 38 networks and/or clinical trial
centres in February 2009, two working groups with
members of identified networks were established and
were tasked to elaborate:
1. The structure for the operation of the European
Paediatric network.
2. Recognition criteria for existing networks which will
have to be fulfilled to become a member of ENPR-EMA
(the European Paediatric Research Network at the
EMA) [3,5,6].
The aim of the second workshop was to discuss with
the networks the proposals elaborated by the two work-
ing groups, and to come to an agreement on the recog-
nition criteria and the structure for the operation of
ENPR-EMA. Twenty-two networks were represented by
27 participants.
The first session was dedicated to discussing the struc-
ture for the operation of ENPR-EMA. The implementa-
tion strategy for ENPR-EMA adopted by the EMA
Management Board proposed to create a ‘Coordinating
Group’ which would contribute to the short and long-
term strategy of the network, discuss and solve opera-
tional and scientific issues for the network, report to the
Paediatric Committee and act as a forum for
communication.
“Coordinating Group”
The chair of Working Group 1 presented their proposal
for the composition of the Coordinating Group:
￿ The Coordinating Group should a) be as diverse as
possible, b) inclusive to represent various types of net-
works: networks focusing on specific therapeutic areas,
specific needs/age subsets (e.g. neonatal/adolescent net-
works) or specific activities (e.g. pharmacovigilance), as
well as organizational, transversal networks (e.g. national
networks linking together either several clinical trial
centres or community paediatricians), accommodating
for regional differences throughout Europe with regards
to how the medical care of children is organised.
￿ According to the implementation strategy the total
number of members shall not exceed 20, including one
member representing the EC and 2 members of the Pae-
diatric Committee. Thus the Coordination Group will
consist of 18 members of existing and recognised net-
works. The working group could not agree that initially
all networks meeting the recognition criteria would
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Group, whereas other networks would then have to
group themselves to be represented, once the maximum
number had been reached.
The composition of the Coordinating Group
￿ 4 networks representing national networks
￿ 10 members representing diverse therapeutic areas:
- Oncology/Haematologic Malignancies
- Diabetes/Endocrinology/metabolic disorders/
Gynaecology
- Gastroenterology/Hepatology
- Allergology/Immunology/Rheumatology
- Stem Cell and Organ Transplantation/Haematology
(non malignant)/Haemostaseology
- Respiratory diseases/Cystic Fibrosis
- Cardiovascular diseases/Nephrology
- Psychiatry/Neurology
- Infectious diseases/Vaccinology
- Intensive Care/Pain/Anaesthesiology/Surgery
￿ 4 members representing special activities/age groups:
- 1 member from European neonatal network
- 1 member representing European paediatric phar-
macists
- 1 member representing special activities, eg pharma-
covigilance, long-term follow up, Phase 4 studies eg via
network of community paediatricians
- 1 member representing expertise in clinical trial
methodology. This member could also represent net-
works not actually performing clinical trials (such as
TEDDY, PRIOMEDCHILD).
The tasks of the Coordinating Group
The main tasks identified were:
- to facilitate access for industry to paediatric clinical
study sites (e.g. coordinate industry requests/enquiries/
feasibility) to the Networks/Centres of Excellence/
experts/societies.
- to act as a platform to communicate and negotiate
with industry
- to work on agreement/contracts with pharmaceutical
industry regarding paediatric trials
- to identify networks which are not yet on the
Agency list
- to develop common educational tools for patients/
parents to increase willingness to participate in paedia-
tric trials
- to help ensure feasibility of studies and monitor trial
recruitment so that feasibility can be maintained [3,5,6].
Recognition criteria and self-assessment report
The chair of Working Group 2 informed the partici-
pants how the criteria were elaborated, using both the
Delphi technique for the first and second round, and
the Nominal group technique in the face-to-face meet-
ing held in December 2009 at the EMA [7].
In the first round of the Delphi survey, all 62 networks
identified were asked for suggestions of recognition cri-
teria. Thirty replies (30/62, 48%) were received including
one from EMA. Similar proposals were grouped within
8 categories in order to obtain a list of the most cited
criteria. Only criteria that can be quantified, either qua-
litatively (e.g. yes or no or other scales) or quantitatively
(e.g. numbers) were taken into account.
In the second round, sent again to the 62 networks,
responders were asked to rank the 8 categories from 8
for the most important, to 1 for the least important.
Within each of the 8 categories, responders were asked
to select one or several essential items that are impor-
tant to quantify the related category.
The response rate to the second round was 45/62
(73%): 41 completed the survey, 4 refused and 17 did
not reply. Based on these responses, the members of
both working groups were invited to a consensus con-
ference at EMA with the goal to establish the final list
of criteria. During this meeting the final list was con-
densed to the following 6 categories, each with several
sub-categories:
1. Research experience and ability (13 subcategories)
2. Network organisation and processes (10 sub-
categories)
3. Scientific competencies and capacity to provide
expert advice (7 subcategories)
4. Quality management (7 subcategories)
5. Training and educational capacity to build compe-
tences (5 subcategories)
6. Public involvement (3 subcategories)
The last part of the workshop was dedicated to defin-
ing minimum recognition criteria to become a member
of ENPR-EMA. There was general consensus on a
definition of a minimum set of criteria based on the
following:
- Recognition criteria are related to quality of research
- A minimum level of quality must be provided
- The intention is to be open to new/emerging net-
works and organisations.
The minimum requirements agreed were:
At least 1 ongoing or completed trial (Criterion 1)
An identified contact person (Criterion 2)
An external or internal Advisory Board (Criterion 2)
Internal patient database or disease registry (Criterion 2)
Individual data protection and data security (Criterion 2)
Access to experts/expert groups (Criterion 3)
Capacity to answer scientific questions (Criterion 3)
Compliance with GCP (Criterion 4)
Compliance with Ethical Considerations (Criterion 4)
Monitoring Capacity (internal or external) (Criterion 4)
Quality control (Criterion 4)
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development (Criterion 5)
Training received/given (Criterion 5)
Involvement of patients in either protocol design, or
patient information package, or prioritisation of needs
for clinical trials (Criterion 6)
Following the publication of research quality require-
ments, a set of recognition criteria, which have to be
fulfilled to become a member of ENPR-EMA were
agreed [8]. So far, 32 networks and centres (of 62 iden-
tified networks) submitted self-assessment reports
indicating whether or not they fulfill the agreed mini-
mum criteria.
Sixteen networks (26% of 62 identified networks) ful-
filled all minimum criteria and became therefore mem-
bers of ENPR-EMA. Three networks still having to
clarify some issues before fulfilling criteria; the other
networks currently not fulfilling minimum criteria.
The FIMP-MCRN [9-11], member of ENCEPP (Eur-
opean Network of Centres for Pharmacoepidemiology
and Pharmacovigilance), became member of the ENPR-
EMA responding satisfactorily to all the points of the
self-assessment report [12].
The FIMP-MCRN was established in 2003 with the
aim of developing competence, infrastructure, network-
ing and education for paediatric clinical trials. It has
been created to improve international standards of
ethics and scientific quality by means of an agreement
between individuals co-operating for the same objec-
tives, goals and quality standards. The FIMP - MCRN
have developed and improved expertise in: observational
and epidemiological studies; efficacy studies; safety stu-
dies according to the Law - M.D. 139/2001 (this Law
expresses the possibility of family pediatricians to per-
form Phase 3 and Phase 4 in their ambulatories) [11].
The FIMP-MCRN has got a system of management
of the quality, a Quality Control, a Quality Assurance
and a traceability, a transparency and a data safety.
Furthermore, ad hoc training programs have incremen-
ted knowledge about clinical trials in Family Paediatri-
cians to build up the necessary competencies, to
facilitate co-operation, and to avoid duplication of stu-
dies [11].
List of networks members of EnprEMA and other
networks not yet fulfilling all criteria [12]
Networks fulfilling all minimum criteria:
ITCC (Innovative Therapies for Children with Cancer)
Newcastle-CLLG (Newcastle CCLG Pharmacology
Studies Group)
IBFMSG (Network of National Study Groups for the
treatment of hematological malignancies)
ECFS - CTN (European Cystic Fibrosis Society-
Clinical Trials Network)
MCRN-UK [National Institute for Health Research
(NIHR) Medicines for Children Research Network
(MCRN) United Kingdom]
FINPedNet (Finnish Investigators Network for Pedia-
tric Medicines)
EUNETHYDIS (the European Network for Hyperki-
netic Disorders).
EPOC (A European Paediatric Oncology off patent
medicines Consortium)
FIMP-MCRN (Family Paediatricians - Medicines for
Children Research Network)
UKPVG (United Kingdom Paediatric Vaccines Group)
PENTA (Paediatric European Network for the Treat-
ment of AIDS)
MICYRN (Mother Infant Child Youth Research
Network)
Scotmcn (Scottish medicines for children network)
GNN (German Neonatal Network)
PRINTO (Pediatric Rheumatology International Trials
Organisation)
MCRN-NL(Medicines for Children Research Network
- The Nederland)
Networks still having to clarify some issues before ful-
filling criteria:
EBMT (European Group for Blood and Marrow
Transplantation)
CLG (Children Leukemia Group)
CICPed (Paediatric Network of Clinical Investigation
Centers)
Networks currently not fulfilling minimum criteria:
BPDN (Belgian Pediatric Drug Network)
AMIKI (The Paediatric Trial Network)
EuroNeoNet (European Neonatal Network)
JSWG of PRES (Juvenile Scleroderma Working Group
Pediatric Rheumatology European Society)
Neo-circulation (Network in Neonatology)
PENTI (Paediatric European Network for the Treat-
ment of Infection)
RIPPS (Réseau d’Investigations Pédiatriques des Pro-
duits de Santé)
IPCRN (Irish Paediatric Clinical Research Network)
BLF (Swedish Peadiatric Society)
NCCHD (National Center for Child Health and
Development)
IPTA (International Pediatric Transplant Association)
FUTURENEST CLINICAL RESEARCH ESPGHAN
(European society of Gastroenterology, Hepatology and
Nutrition)
Third Workshop on European Network of
Paediatric Research at the EMA (ENPR-EMA)
Once that was set up on ENPR-EMA with the inclusion of
the 16 networks, it was considered necessary to think
about the next step for its completion which provides for
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Network of Paediatric Research at the EMA [13].
The Workshop will be held in London from 11 to 12
March 2011 at the headquarters of the EMA and will be
organized into two separate days.
The first day of the workshop will be dedicated to dis-
cussions between networks to establish the Coordinating
Group of ENPR-EMA and to discuss and to define
priority tasks of the coordinating group.
The second day is being organised with the assistance
of TOPRA (The Organisation for Professionals in Regu-
latory Affairs) where ENPR-EMA will be introduced to
all stakeholders, particularly patient organisations and
clinical researchers and pharmaceutical industry staff
responsible for paediatric studies. The aim is to define
the expectations of the various stakeholders and to offer
the possibility for industry engaged in paediatric clinical
trials and networks to interact.
The main objective is to conduct clinical trials of
pediatric medicines conducted on an ethical basis, with
the methodological quality necessary and with the char-
acter of independent research (the principal investigator
processes the research project and is owner of the data
obtained).
Conclutions and future prospects
The EUPR wants to link together and coordinate existing
networks, establish a platform for communication and
exchange of information between European networks
and share the skills and expertise in order to cut to shape
and influence future development in paediatric research.
The purpose of this article is to disseminate knowl-
edge of the structure and the goals of ENPR-EMA and
to highlight that networking is necessary to build up the
competence, to make co-operation easier and to avoid
duplication of studies.
The Family Paediatricians Medicines for Children
Research Network (FIMP-MCRN), established with the
aim of developing competence, infrastructure, network-
ing and education for paediatric clinical trials, became
member of this European network. Quality and ethical-
ity of research are becoming important end-points of
Family Paediatricians during their education and during
the sponsoring of health and prevention in the paedia-
tric age groups. These possibilities could grant new pae-
diatric medicine research opportunities and challenges
for FIMP-MCRN and could guarantee further exchange
of experience and competence, being an important
wedge in the cultural mosaic of paediatric research [9].
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